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Abbreviations: DDR, DNA damage response; RFLP, 
restriction fragment length polymorphisms; BMI, body mass index
Introduction
Radiation therapy is part of the multidisciplinary approach to 
breast cancer treatment. Together with surgical or systemic therapy, 
it is most commonly used to reduce loco-regional recurrence and 
promote survival.1 However, the adverse effects that may develop 
during the course of its application deserve special attention. Skin 
reactions begin with mild erythema and desquamation and can 
progress to necrosis and ulceration, preventing the continuity of 
applications and leading to treatment prolongation or suspension.2 
Several reports mention that inter-individual variability in normal 
tissue is a multifactorial trait which depends on treatment parameters, 
clinical factors, lifestyle factors and the genetic component.3 Genes 
related to DNA damage/repair and oxidative stress can be singular 
candidates for evaluating this phenotype. Here, we present a case 
of serious clinical side effects related to radiation, which were not 
expected considering the radiotherapy scheme administered and the 
patient data. We determined individual radiosensitivity at the level of 
DDR in peripheral blood lymphocytes. For this we used the comet 
assay and the analysis of RFLP. However, we believe that while these 
molecular tools are important, there are also other fundamental factors 
that should not be ignored in the analysis of this phenotype.
Case presentation
We investigated a case of a 54 year-old female patient suffering 
from right breast cancer. Two months prior to the radiant treatment, 
the patient was subjected to surgical quadrantectomy and axillary 
lymph node dissection. The intraductal tumor was treated with a 
radiotherapy uniform 3D neoadjuvant protocol that involved the whole 
breast volume. The total dose was 5000 cGy delivered in 25 sessions 
of 2.0 Gy/day. The dose was delivered with 4 MeV photons (Varian 
Clinac). Additionally, a high-dose rate brachytherapy boost of 10 Gy 
was delivered to the nodular region. Moreover, adjuvant treatment 
with Anthracyclines was used. Evaluations in the treatment area 
were performed weekly until radiotherapy completion. The patient 
developed toxicity Grade III, during the third week of treatment. The 
injuries consisted of confluent moist desquamation, severe edema and 
mild ulcerations. Consequently, the treatment was suspended for 15 
days and baths with sodium borate and application of betamethasone 
cream were prescribed.
Clinical and personal data
Histopathological diagnosis: high-grade ductal carcinoma 
in situ with multifocal invasion areas; tumor size of 13x10mm; 
absence of metastases in 13 nodes; HR(-); HER-2/neu(+). Physical 
examination: large breasts; scar from surgery and thorax X-Ray 
without complications; no evidence of hypertension, diabetes, 
hyperthyroidism, smoking or radiosensitivity syndromes; BMI: 
35.06. Family history: Maternal line: grandmother with breast cancer; 
most uncles and cousins with cancer; grandfather with cancer of 
the esophagus and throat. Paternal line: no record. Ancestry: Italian 
descent.
Analysis of individual radiosensitivity
We used the alkaline comet assay to determine DNA repair 
efficacy.4 Asymptomatic patients (n=18) with the same treatment and 
tumor type were used as control. Moreover genes of oxidative stress 
(GSTP1; SOD2; NOS3; GSTA1), DNA repair (XRCC1) and TP53 
were analyzed by RFLP, and compared with a database of medical 
records of 89 patient with the same pathology and radiation treatment. 
Also, a database of 122 patients from the same Institute was used as 
control for the analysis of clinical variables. In our patient case, age 
did not correlate with data of our control database, which showed a 
tendency to these reactions in older women (mean 59.6 years old). 
On the other hand, a high association was observed between the 
development of acute effects and breast size (p=0.001; χ2=18.33), 
namely, 91.67% of patients with grade≥2 radiodermatitis in the control 
database had medium or large breasts, the same as in the case reported 
here. In our patient case, BMI was greater than 25 (35.06), indicating 
obesity or overweight. It was observed that overweight or obese 
individuals mainly manifested severe effects (p=0.006, χ2=14.64). 
In relation to menopausal status, smoking and hormone therapies, 
differences were not significant to justify patient radiodermatitis.
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Abstract
A case of a patient with a breast intraductal tumor is presented. The patient underwent 
surgical quadrantectomy and axillary lymph node dissection and subsequently received 
Anthracycline treatment and 3D radiotherapy following a standard fractionation protocol. 
This case was characterized by the development of grade III dermal toxicity, some 
associated genetic polymorphisms and DNA damage were analyzed. We concluded that 
radiotoxicity is a multifactorial phenotype that should be addressed in a broader context, 
considering not only intrinsic variables but also criteria such as breast size, body mass index 
and concomitant treatments, among others.
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The effectiveness of the repair mechanisms did not differ 
between this patient and the control group (Figure 1). Immediately 
after irradiation (T0), moderate DNA damage was observed in both, 
patient and control group. Additionally, damage was significantly 
greater that observed in controls without irradiation, and at T60 and 
T120 min post-irradiation (p<0.0001). Regarding polymorphism, 
SNPs were observed for NOS3 G894T, GSTA1 C69T, XRCC1 
R399Q and TP53 R72P; the genotypes determined were G/T, C/T, 
A/A, C/G, respectively. No changes were observed for genes GSTP1 
A313G (A/A) and SOD2 T47C (T/T).  We also found a significant 
association between NOS3 G894T polymorphisms and grade ≥2 acute 
skin radiotoxicity in patients with neo-adjuvant chemotherapy in our 
control database, just as in the study case (OR=14.7; p=0.03). 
Figure 1 Repair kinetics of in vitro irradiated lymphocytes in the patient and 
control groups. Damage index (DI, expressed in arbitrary units) vs the time 
elapsed after irradiation is shown. ****p<0.0001 vs Control, T60 (1h) and T120 
(2h); one way ANOVA and Tukey’s multiple comparisons test a posteriori. 
Results are expressed as mean±SEM.
Discussion
Clinical radiosensitivity is a dynamic process that involves the 
gradual evolution of complex lesions.5 Around the turn of the century, 
there was growing consensus that this phenotype should be considered 
as a polygenic feature that depended on the combined influence of 
several risk alleles.6 Nevertheless, this phenotype is better understood 
as a multifactorial trait, where other external factors participate along 
with genetic polymorphisms.1,6,7 In relation to these elements, we 
validate the association of radiotoxicity with breast size, BMI and 
antineoplastic treatment, in coincidence with Back et al.8 In cellular 
terms, unlike other authors,9 we did not detect abnormalities in the 
initial damage and DNA repair capacity after in vitro irradiation. 
The dynamics of DNA repair observed in the patient show a good 
kinetics of cell recovery, with a reduction in radio-induced genomic 
damage in T60 and similar residual damage with the control group. 
In reference to polymorphisms, although the state of TP53 and 
XRCC1 could confer some genomic instability, the influence of these 
genotypes on the acute radio-toxicity of our patient could not be 
verified. On the other hand, it is known that the activity of antioxidant 
enzymes can influence the effectiveness of radiotherapy and thus it is 
plausible that their polymorphic variants affect the development of 
the side effects.10 We could not corroborate this statement in relation 
to GSTP1, SOD2 and GSTA1 polymorphism. However, results of 
NOS3 G894T polymorphism agreed with previous results10 regarding 
the occurrence of acute radiation skin toxicity in patients with neo-
adjuvant chemotherapy. In this sense, some authors mentioned 
that chemotherapy increased skin reactions, and treatments with 
anthracycline interfered in their intensity.2,10
As a corollary of our analysis and considering that radiosensitivity 
is a multifactorial trait, different elements must be considered together 
with the polygenic component. Although radiogenomics led to a 
better understanding of the pathways involved in the determination 
of this phenotype, the involvement of the tissue microenvironment 
forces us to evaluate this response at a broader level of complexity 
not yet clarified. We believe that variables such as breast volume 
and BMI should be considered at the beginning of treatment and 
subsequently integrated into a broader analysis model that includes 
intrinsic variables such as the individual’s radiogenomic profile. The 
therapeutic approach is not only important for the local control of the 
disease but also for the implications for the patient’s quality of life. It 
is essential to identify solid factors that predict the course of treatment 
in relation to its adverse effects, especially in patients at high risk of 
suffering unwanted effects on the skin.
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